Tweed, C. D., Dawson, R., Burger, D. A., Conradie, A., Crook, A. M., Mendel, C. M., . . . Spigelman, M. (2019). Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: A multicentre, open-label, partially randomised, phase 2b trial. Lancet Respir Med.
シカゴスタイル引用形Tweed, Conor D., et al. "Bedaquiline, Moxifloxacin, Pretomanid, and Pyrazinamide During the First 8 Weeks of Treatment of Patients With Drug-susceptible or Drug-resistant Pulmonary Tuberculosis: A Multicentre, Open-label, Partially Randomised, Phase 2b Trial." Lancet Respir Med 2019.
MLA引用形式Tweed, Conor D., et al. "Bedaquiline, Moxifloxacin, Pretomanid, and Pyrazinamide During the First 8 Weeks of Treatment of Patients With Drug-susceptible or Drug-resistant Pulmonary Tuberculosis: A Multicentre, Open-label, Partially Randomised, Phase 2b Trial." Lancet Respir Med 2019.